MARKET

CTXR

CTXR

Citius Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9054
-0.0150
-1.63%
After Hours: 0.9286 +0.0232 +2.56% 19:59 05/26 EDT
OPEN
0.9164
PREV CLOSE
0.9204
HIGH
0.9312
LOW
0.8971
VOLUME
1.14M
TURNOVER
0
52 WEEK HIGH
4.560
52 WEEK LOW
0.8600
MARKET CAP
132.31M
P/E (TTM)
-4.4844
1D
5D
1M
3M
1Y
5Y
Citius Pharma to spinoff its immunotherapy I/ONTAK into a new publicly-traded company
Late-stage biopharmaceutical company Citius Pharmaceuticals (NASDAQ:CTXR) on Wednesday said it plans to split into two separate publicly-traded entities. CTXR said it would form a new company focused on developing and
Seekingalpha · 1d ago
Citius Pharmaceuticals, Inc. Announces Intention To Spinoff Late-Stage Oncology Asset, I/ONTAK, Into A New Standalone Publicly Traded Company
IPO with distribution of shares to Citius shareholders planned for 2H 2022 Citius would retain Mino-Lok and other pipeline assets and continue to trade on Nasdaq (ticker: CTXR) CRANFORD, N.J., May 25,
Benzinga · 1d ago
Citius Pharmaceuticals Plans to Spin Off Its Oncology Business
MT Newswires · 1d ago
Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it will present at the H.C. Wainwright Global Investm...
PR Newswire · 05/18 13:30
Citius Pharmaceuticals GAAP EPS of -$0.05 beats by $0.02
Citius Pharmaceuticals press release (NASDAQ:CTXR): Q2 GAAP EPS of -$0.05 beats by $0.02. Topline results of Phase 3 trial in cancer immunotherapy I/ONTAK consistent with prior formulation; BLA submission on
Seekingalpha · 05/12 20:38
BRIEF-Citius Pharmaceuticals Reports Fiscal Q2 2022 Results
reuters.com · 05/12 20:35
Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Shift From Loss To Profit
Citius Pharmaceuticals, Inc. ( NASDAQ:CTXR ) is possibly approaching a major achievement in its business, so we would...
Simply Wall St. · 05/11 11:34
10 Penny Stocks to Buy in May
In this article, we will look at 10 penny stocks to buy in May. If you want to explore similar stocks that have the potential to explode in the future, you can also take a look at 5 Penny Stocks to Buy in May. Predicting the future might be a little far-fe...
Insider Monkey · 05/10 15:10
More
No Data
Learn about the latest financial forecast of CTXR. Analyze the recent business situations of Citius Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CTXR stock price target is 6.67 with a high estimate of 10.00 and a low estimate of 4.000.
High10.00
Average6.67
Low4.000
Current 0.9054
EPS
Actual
Estimate
-0.06-0.04-0.03-0.01
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 83
Institutional Holdings: 24.71M
% Owned: 16.91%
Shares Outstanding: 146.13M
TypeInstitutionsShares
Increased
20
622.39K
New
7
67.48K
Decreased
24
607.90K
Sold Out
9
488.21K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Chairman/Chief Executive Officer/Executive Director/Secretary
Leonard Mazur
Vice Chairman/Executive Director
Myron Holubiak
Chief Financial Officer
Jaime Bartushak
Executive Vice President
Myron Czuczman
Vice President/IR Contact Officer
Ilanit Allen
Vice President
Michael McGuire
Lead Director/Independent Director
Howard Safir
Independent Director
Suren Dutia
Independent Director
Eugene Holuka
Independent Director
William Kane
Independent Director
Carol Webb
No Data
No Data
About CTXR
Citius Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on development of critical care products, such as anti-infective products in adjunct cancer care, prescription products and stem cell therapy. The Company has three products: Mino-Lok, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). CITI-002 helps to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap product (CITI-101) is a malleable, bio-absorbable film impregnated with minocycline and rifampin. It is designed to reduce infections associated with the use of breast tissue expanders (TE) used in breast reconstruction surgeries following mastectomies.

Webull offers kinds of Citius Pharmaceuticals Inc stock information, including NASDAQ:CTXR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTXR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTXR stock methods without spending real money on the virtual paper trading platform.